Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FACTOR Study (Filanesib and Carfilzomib in Relapsed/Refractory Multiple Myeloma)
2014-001052-39Phase 3Completed
- Sponsor
- Array BioPharma
- Start
- Sep 2014
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of filanesib, carfilzomib in multiple myeloma (MM), sponsored by Array BioPharma. Started Sep 2014; status: completed.
02
Drugs
filanesibcarfilzomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2014-001052-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001052-39.